Neuro oncology News and Research

RSS

UCSF scientists develop smart CAR-T cells to fight childhood brain tumors

Scientists at UC San Francisco have engineered CAR-T cells that stay dormant until they reach the brain, where they switch on and destroy tumor cells.

28 Oct 2026

Cerebrospinal fluid liquid biopsy detects tumor DNA in complex brain cases

A Mayo Clinic study published in the Journal of Neuro-Oncology suggests that analyzing DNA in cerebrospinal fluid could provide another source of information when MRI cannot provide a clear brain tumor diagnosis or obtaining tissue through biopsy is difficult or potentially unsafe.

27 Oct 2026

Altered fatty acid metabolism drives glioblastoma growth and treatment resistance

Glioma is the most common primary malignant brain tumor in adults, and glioblastoma (GBM), particularly IDH (Isocitrate dehydrogenase)-wildtype disease, has the poorest prognosis.

21 Oct 2026

Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study

Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing clinical Window-of-Opportunity (WoO) study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma.

9 Oct 2026

Combination therapy overcomes immunotherapy resistance in glioblastoma

Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma.

8 Oct 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown.

17 Sep 2026

Aging brain actively shapes biology and progression of tumors

Brain tumors develop within an organ that changes substantially with age. A new review in Ageing and Cancer Research & Treatment examines evidence that the aging brain microenvironment may influence brain tumor progression, treatment resistance, and cognitive outcomes.

10 Sep 2026

Giving immunotherapy before surgery boosts brain tumor treatment success

A team from UNIGE and HUG has shown that administering cell immunotherapy before surgery to remove a brain tumor is significantly more effective than administering it afterwards.

2 Sep 2026

Study reveals why diffuse midline glioma develops in brain midline regions

Scientists at St. Jude Children's Research Hospital have shown that specific brain cells respond differently to the H3.3 K27M, a mutation in the histone H3.3 protein that drives many cases of diffuse midline glioma (DMG), depending on the cell's location in the developing brain.

27 Aug 2026

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

LVIS stent-assisted coiling effectively treats wide-necked intracranial aneurysms

Intracranial aneurysms are weakened, bulging areas of cerebral arteries that can rupture, causing subarachnoid hemorrhage and, in turn, significant disability or death.

11 Aug 2026

Immune cell interaction timing impacts glioblastoma treatment response

A joint research team led by Professor Sungsu Park of Sungkyunkwan University and Professor Sun-Ha Paek of Seoul National University College of Medicine has demonstrated for the first time that the sequence in which immune cells interact with cancer cells can critically influence the therapeutic response in glioblastoma.

10 Aug 2026

Researchers find potential pathway to improve glioblastoma treatment

New research published in Neuro-Oncology gives a glimpse at promising discoveries that could help shape the future of glioblastoma treatment and patient outcomes.

29 Jul 2026

New human tissue model tracks aggressive brain tumor infiltration

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs.

28 Jul 2026

Robot-guided surgery successfully drains multiple deep brain abscesses

Brain abscesses located deep within the brain can rapidly become life-threatening and are often difficult to treat through conventional surgery. Brain abscesses located deep within the brain can rapidly become life-threatening and are often difficult to treat through conventional surgery.

13 Jul 2026

CAR-T cell therapy shows potential to eliminate aggressive glioblastoma

A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and attack cancer, could be used to treat glioblastoma.

1 Jul 2026

Vitamin B12 analog targets deadly brain cancer cells

A new research paper was published in Volume 13 of Oncoscience on April 2, 2026, titled "Selective blood–brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with trail and temozolomide."

21 May 2026

Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma

A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for glioblastoma, the most aggressive and most common type of primary brain cancer in adults.

13 May 2026

Multi-center research initiative aims to improve glioblastoma patient outcomes

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center are part of a new multi-institution research effort aimed at improving care and outcomes for patients diagnosed with glioblastoma, one of the most aggressive and difficult-to-treat cancers.

8 May 2026

Hyperbaric oxygen therapy shows dual effects in glioblastoma treatment

Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment is a key contributor to its therapy resistance.

23 Apr 2026